Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, launched LentiSure, an optimized Lentiviral (LV) Vector manufacturing platform for increasing lentivirus production efficiency and robustness. Lentivirus or LV vectors are used to produce cell-based immuno-oncology therapies. Their robustness as a gene delivery system is vital in determining the success of any cell-based cancer treatment. 
 
LentiSure’s capabilities in producing LV vectors with consistent product quality, the overall average titers at cell culture harvest is at 10e7 IG/mL bioreactor volume, offer cell therapy developers higher productivity and a higher probability of achieving the desired outcomes, according to the company. 
 
“Yposkesi is pleased to launch LentiSure, a novel and key asset able to deliver consistent yields of lentivirus vectors at the higher end of what we see on the market today,” said Alain Lamproye, chairman and CEO of Yposkesi. “This optimized LV platform is the outcome of our long-standing work in bioprocess innovation. It meets the challenges in producing cell-based immuno-oncology treatments, which is driving growth in the cell and gene therapy market, notably with the development of CAR-T cell treatments. Two new CAR-T products were approved last year in the US, with six products already on the market in both the US and Europe, along with several pending approvals. LentiSure’s scalable, high yield and high-quality lentiviral process brings net advantages to CAR-T developers and competitively positions Yposkesi as a leading European CDMO for viral vectors.” 
 
To optimize its LV platform, Yposkesi has increased efficiency at each manufacturing step. Key to this was optimizing and reducing the complexity across manufacturing unit operations, including step performance, and time and materials management. According to the company, this translates into benefits in relation to client timelines, as they become more predictable for cell therapy development, and in overall costs, through optimized inputs and operations.